用重组人神经生长因子（cenegermin）治疗准分子原位角膜磨镶术后干眼症
Treatment of Dry Eye from Laser-Assisted In Situ Keratomileusis With Recombinant Human Nerve Growth Factor (Cenegermin).
作者信息
Habibi Roya N, Lee Michele D
机构信息
Eye Associates Northwest, P.C., Seattle, WA; and.
Department of Ophthalmology, University of Washington, Seattle, WA.
出版信息
Cornea. 2021 Aug 1;40(8):1059-1061. doi: 10.1097/ICO.0000000000002554.
PURPOSE
To describe 2 patients with neurotrophic keratitis after laser-assisted in situ keratomileusis surgery who were treated with recombinant human nerve growth factor (cenegermin) and the treatment course.
METHODS
Case series.
RESULTS
After an 8 week course of cenegermin, there was an improvement in visual acuity, corneal sensitivity, and ocular surface staining. However, these effects were short lived, and the disease regressed at subsequent follow-up visits.
CONCLUSIONS
Although recombinant human nerve growth factor seems to be effective in short term for neurotrophic keratitis secondary to laser-assisted in situ keratomileusis surgery, alternative dosing for patients with this patient population should be considered to achieve long-lasting resolution.
目的
描述2例接受准分子原位角膜磨镶术（LASIK）后发生神经营养性角膜炎的患者，他们接受了重组人神经生长因子（cenegermin）治疗及其治疗过程。
方法
病例系列研究。
结果
经过8周的cenegermin治疗后，视力、角膜敏感性和眼表染色情况有所改善。然而，这些效果是短暂的，在随后的随访中病情复发。
结论
尽管重组人神经生长因子似乎在短期内对准分子原位角膜磨镶术继发的神经营养性角膜炎有效，但对于该患者群体，应考虑采用其他给药方案以实现持久缓解。
Zotero 插件